Actively Recruiting
Long Term Outcomes After Oral Immunotherapy for Peanut, Egg, and Cow's Milk Allergy (LPEM Study)
Led by Murdoch Childrens Research Institute · Updated on 2026-02-02
147
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the long-term outcomes of children and young people who completed an 18-month course of oral immunotherapy (OIT) for peanut, egg, or milk allergy. The study aims to compare changes in health-related quality of life (HRQL) up to 5-15 years after stopping OIT, focusing on participants who achieved remission and those who did not. This observational study involves participants from four earlier clinical trials related to OIT treatment for these allergies. Participants will attend one follow-up visit where several tests and evaluations will take place. These include a blood test to measure specific immunoglobulin E (sIgE) levels related to peanut, egg, or milk allergies, and a skin prick test to assess allergy status using various extracts like histamine, saline, house dust mite, rye grass, and the relevant food allergen. Blood collection may be via venipuncture or fingerprick depending on feasibility. Plasma and blood cells will be stored for future research. During the single study visit, participants will complete allergy questionnaires, and blood and skin tests will be conducted to gather data on immune markers and allergy status. Researchers will measure changes in HRQL and the incidence and severity of allergic reactions over the years following OIT. The visit is expected to last about two hours, and results will help understand the long-term effects of OIT on food allergy remission and quality of life.
CONDITIONS
Brief Title
A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Previous participant of PEAT, PrEMO, PPOIT-001, or PPOIT-002 parent study
- Received at least one dose of oral immunotherapy treatment in the parent study
- Written informed consent from participant and/or parent/guardian if under 18 years old
You will not qualify if you...
- Any condition that the investigator believes makes participation unsafe
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single visit at 5 to 15 years post-treatment
Participants attend a single study visit 5 to 15 years after completing oral immunotherapy to evaluate long-term outcomes including allergy status and quality of life.
1 visit (approximately 2 hours, in-person)
Trial Site Locations
Total: 1 location
1
Murdoch Children's Research Institute
Parkville, Victoria, Australia, 3052
Actively Recruiting
Research Team
A
Adriana Chebar Lozinsky Rolnik
A
Amanda Burgess
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here